Sector News

AstraZeneca sells migraine drug for up to $302 million

June 8, 2017
Life sciences

AstraZeneca continued its program of divesting old medicines on Wednesday with the sale for up to $302 million of migraine drug Zomig to Germany’s Grunenthal.

The British firm, which is betting on new drugs for cancer and other diseases to revive its fortunes, has sold or licensed out a raft of aging products recently. Some analysts have criticized the trend for unduly propping up its earnings.

Grunenthal will acquire global rights to Zomig in all markets outside Japan, paying AstraZeneca $200 million upon completion of the deal. AstraZeneca will also receive up to $102 million in future milestone payments.

In 2016, AstraZeneca’s revenue from Zomig outside Japan was $96 million.

The two companies added that Impax Pharmaceuticals, which had previously licensed rights to the drug in the United States, would continue to sell Zomig in that market.

For Grunenthal – best-known as the company that initially developed thalidomide as a morning sickness drug – the acquisition builds up its growing business in pain products.

Chief Executive Gabriel Baertschi said it was an important step in reaching the group’s ambition to become a company with 2 billion euros ($2.25 billion) of sales by 2022. Sales in 2016 totaled around 1.4 billion euros.

Like other recent drug divestments, the Zomig agreement does not impact AstraZeneca’s financial guidance for 2017.

By Ben Hirschler

Source: Reuters

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach